Enhanced Lifestyles for Metabolic Syndrome (ELM)

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Behavioral intervention, Lifestyle Read More

Inclusion Criteria:

1. Men and women with metabolic syndrome, defined by the Joint Interim Statement of the IDF, NHLBI, AHA, WHF, IAS, IASO (Alberti, 2009). Note that hemoglobin A1c will be measured as a marker of impaired glucose metabolism, but will not be considered in determining metabolic syndrome status. To meet metabolic syndrome criteria the participant should have ≥ 3 of the following five criteria:

   • Waist circumference based on AHA/NHLBI (ATP III) cut points of ≥ 102 cm for men and ≥ 88 cm for women
   • Fasting triglycerides ≥150 mg/dL or treatment for elevated triglycerides
   • Fasting HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or treatment for low HDL
   • Systolic blood pressure ≥130 m Hg, diastolic blood pressure ≥85 mm Hg, or treatment for hypertension
   • Fasting plasma glucose 100-125 mg/dL (range inclusive)
2. Greater than 18 years of age

Exclusion Criteria:

1. Unable to walk 2 consecutive blocks without assistance, based on patient report.
2. Unwilling, unable, or not ready to make the lifestyle changes prescribed in ELM
3. Unwilling to be randomized to either arm of the trial
4. Unable or unwilling to give an informed consent, communicate with study staff, or complete the study run-in period. The run-in period requires attending an information session, completing two assessment visits within the scheduled time (potential participant is allowed to reschedule once), wearing an accelerometer, and completing lifestyle logs (see protocol)
5. Does not have reliable access to the internet via a computer or mobile device
6. Not fluent in English
7. Current diagnosis of type 1 or type 2 diabetes, or on any diabetes medications except metformin
8. Inpatient treatment for a psychiatric condition within the past 6 months, or currently receiving treatment for schizophrenia or other serious psychiatric illness
9. Probable major depression, defined as a PHQ-8 score ≥10
10. Pregnant women, planning a pregnancy in the next 24 months, given birth in the last 6 months, or currently breastfeeding
11. ≥ 30 total days of oral corticosteroid use within the last year, history of solid organ transplant, or history of stem cell transplant
12. Problematic use of alcohol and/or recreational drugs based on the ASSIST screening tool (score of ≥27).
13. Self-reported or known history of an eating disorder (e.g., binging and purging) in the past 5 years
14. Use of weight loss medications (Qsymia, phentermine, etc.) or supplements in the last 3 months, or unwilling to abstain from taking weight loss medications or supplements during the study
15. History of bowel resection surgery or bariatric surgery
16. Participant does not have, or is unwilling to seek care from, a primary care physician at the time of enrollment
17. Any medical condition known to influence the etiology of MetS as judged by the study physician (e.g., uncontrolled hypothyroidism, endocrine hypertension, etc)
18. History of major cardiovascular illness, including a) stroke; b) myocardial infarction; c) congestive heart failure requiring hospitalization, or greater than NYHA heart failure class I; d) uncontrolled hypertension (SBP>180 or DBP > 105); e) unstable angina; or f) other major cardiovascular illness which the site PI determines could limit ability to participate in the trial.
19. Behavioral/logistical barriers to trial participation or engagement, e.g., a scheduled major surgery, scheduling difficulties, travel plans, moving outside the study area
20. Cognitive impairment, defined by a Montreal Cognitive Assessment (MoCA) score of ≤25. The MoCA will be administered only when research staff suspect cognitive impairment
21. Visual or hearing impairment
22. Severe food allergies or food intolerances/preferences that preclude participation in the ELM program

23. Currently taking or expecting to take any of the following exclusionary medications:

    1. Antiretroviral therapy (e.g., HAART)
    2. Weight loss medications (as in #14)
    3. Medications known to significantly influence weight or metabolic outcomes
    4. Diabetes drugs other than metformin (as in #7)
24. Participation in any clinical trial, until at least six months following the end of the intervention phase. Individuals in long-term follow-up (over 6 months post intervention) may be enrolled in ELM.
25. Cancer treatment within the last 6 months, excluding chemoprophylaxis or treatment for non-melanoma skin cancer.
26. Previous participation in an ELM program or currently living with ELM participant.